CHMP5 and COVID-19: Interestingly, the Pfizer phase I/II COVID-19 vaccine trial with BNT162b1, an mRNA that encodes the RBD of the spike protein, showed that a detectable level of RBD-binding IgG was seen before the second dose, but the peak was 1 week after the booster (31).